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in cultured ovarian carcinoma cells
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Summary In ovarian carcinoma cells, the combination of interferon-y (IFN-y) and cisplatin (cDDP) has been reported to result in a synergistic
amplification of antiproliferative activity. To assess whether IFN-y may also prevent the occurrence of cisplatin resistance, the human ovarian
carcinoma cell line HTB-77 was treated repeatedly in an intermittent fashion with either cisplatin alone (HTB-77cDDP) or cisplatin plus IFN--y
(HTB-77cDDP+ IFN). After 8 months of treatment, both new lines (HTB-77CDDP or HTB-77CDDP+IFN) were found to be three times more resistant to
cisplatin than the wild-type cells (HTB-77ft,). IFN-ycould not prevent the development ofcisplatin resistance. Interestingly, both HTB-77CDDP and
HTB-77CDDp+IFN cells were also less IFN-ysensitive than the parental line. Both cisplatin-resistant lines expressed p185HER-2 and HER-2 mRNA
at a higherconcentration than theHTB-77w,, cells. IFN-ywas in all three HTB-77 cell lines able to suppress the HER-2 message and its encoded
protein. The expression of IFN-y-induced antigens, namely CA-125 and class 11 antigens of the major histocompatibility complex (HLA-DR),
was markedly augmented by IFN-yin all three lines, whereby the most prominent effect was seen in HTB-77CDDP and HTB-77CDDP +IFN.
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Cisplatin (cDDP) is the most commonly used agent for the treat-
ment of ovarian cancer. Unfortunately, the clinical use of cisplatin
is limited by its toxic profile and by the frequent development of
resistance (Andrews and Howell, 1990). At present, the dominant
mechanism responsible forclinically acquired resistance is unclear.
Possible mechanisms of resistance to platinum compounds as
identified in different ovarian tumour cell lines can be divided
into decreased drug accumulation, altered drug inactivation and
increased repair of DNA damage (for review van der Zee et al,
1995). Modification of proto-oncogene expression has also been
considered as an interesting possibility for tumour cells to over-
come the toxic effect of cisplatin (Hancock et al, 1991). This has
also been suggested more recently by Langton-Webster et al
(1994), showing that long-term exposure of HTB-77 cells to
cisplatin results in a decreased expression of the proto-oncogene
HER-2 (c-erb B-2, neu), which encodes an important growth factor
receptor. Interferon-y (IFN-y) is another drug that is able to
suppress HER-2 expression in ovarian carcinoma cells, as has been
demonstrated by reduced specific RNA andpl85HER-2 levels (Marth
et al, 1990). As reduced HER-2 expression has been associated
with increased cisplatin sensitivity, the interaction of IFN-y with
cisplatin in vitro becomes an interesting possibility for modulation
of cytotoxicity: by combining IFN-y with cisplatin we observed a
synergistic effect in HTB-77 and A 2780 ovarian carcinoma cell
lines and only an additive effect in OVCAR-3 ovarian carcinoma
cells (Marth et al, 1989a). The same combination has also been
shown to act in a highly synergistic manner, as demonstrated by
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median-effect analysis, in a cisplatin-sensitive ovarian carcinoma
cell line (2008) and in its tenfold cisplatin-resistant subline
(2008/C13*) (Nehme et al, 1994). Moreover, these authors demon-
strated that IFN-ysensitized the cytotoxic effect ofcisplatin.
In view ofthis synergistic interaction and modulation ofHER-2
expression by interferons and cisplatin, we were interested to
know whether IFN-y could also prevent the development of
cisplatin resistance. We selected HTB-77 ovarian carcinoma cells
for their well-known responsiveness to cisplatin and IFN-,yas well
as HER-2 overexpression (Marth et al, 1989a, 1990). By means of
acute intermittent in vitro treatments with either cisplatin alone, or
in combination with IFN-y, over 8 months two HTB-77 sublines
were selected and characterized for their growth properties.
MATERIALS AND METHODS
Substances
Recombinant DNA-derived human IFN-,y was kindly donated by
Dr G Adolf, Bender, Vienna, Austria. The preparation was essen-
tially pure and had a specific activity of2 x 107 antiviral U per mg
of protein. Cisplatin was provided by Bristol-Myers-Squibb,
Vienna, Austria.
Cell culture
The human ovarian carcinoma cell line HTB-77 (also named SK-
OV-3) was obtained from Dr Christian Dittrich, University of
Vienna, Austria, and was cultured and passaged in Dulbecco's
modified minimum essential medium containing 10% fetal
bovine serum and 2 mM L-glutamine. The HTB-77CDDP and HTB-
77cDDP + IFN cells were developed by intermittent repeated
exposure to either cisplatin (3 ig ml-') alone or a combination of
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IFN-y (10 ng ml-') and cisplatin (3 ,ug ml-') respectively. Cisplatin
was given to both groups simultaneously for 48 h. The interferon
treatment was started in HTB-77CDDP + IFN cells 2 days before the
cisplatin administration and continued concomitantly during the
48 h of cisplatin treatment. Surviving cells were grown to conflu-
ence (2-4 weeks) and retreated for 8 months with a total of 11
incubations. Wild-type HTB-77 (HTB-77w,) cells were grown and
passaged in parallel with two treatment groups.
Cell proliferation
Cells were plated in 24-well tissue culture plates (Nunc, Roskilde,
Denmark) and were allowed to attach overnight. The medium was
changed and cisplatin or IFN-y was added in the desired concen-
trations. The culture medium was renewed every 3 or 4 days. After
7 days ofculture, the number ofcells was enumerated by means of
an electronic particle counter (Coulter, Dunstable, UK).
Surface antigen expression
The expression of antigens belonging to the major histocompati-
bility complex class II (HLA-DR) or CA-125 was detected by a
living cell radioimmunoassay as described previously (Marth et al,
1989b). Briefly, about 50 000 cells were seeded in 96-well tissue
culture plates (Nunc), and after 3 days of treatment with IFN-y
(1Ong ml') the wells were washed with culture medium. The
mouse monoclonal antibody against CA-125 (OC-125 from CIS,
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Table 1 Effects of interferon-y on the expression of CA-125 and HLA-DR in
HTB-77 cells
Cell line CA-125 HLA-DR
Control + IFN-y Control + IFN-y
HTB-77w, <100 727+ 64 <100 1973 + 215
HTB-77cDDP <100 1921 + 181* <100 3319 + 436*
HTB-77cDDP+IFN <100 2682 ± 311 * <100 3652+272*
Cells were treated for 3 days with or without interferon-y (10 ng ml-') and
antigen expression was determined as described in Material and methods.
Results are given as mean counts per min of six wells counted + 1 s.d.
*P< 0.05 vs HTB-77,, cells.
Table 2 Effects of interferon-y on p185HER-2 expression
Cell line Control + IFN-y
HTB-77wt 15 400 ± 1100 5050 + 550**
HTB-77CDDP 19 200 + 1800* 5350 ± 480**
HTB-77cDDP + IFN 24 000+21 00* 6650+510**
Cells were cultured for 3 days with or without interferon-y (10 ng ml-1).
Concentration of p1 85HER-2 was determined as described in Materials and
methods. Results are presented as mean value from six flasks measured
+ 1 s.d. in HER-2/neu units per mg of protein. *P < 0.05 vs HTB-77,t cells;
**P < 0.05 vs control.
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Figure 1 Effects of cisplatin (A) and of interferon-y (B) on the proliferation of HTB-77 cells. HTB-77,,, (0); HTB-77CDDP (A); and HTB-77CDDp+ IFN (°Z) cells were
cultured in the presence of cisplatin (A) or interferon-y (B) for 7 days. Each point represents the mean number of cells of six wells counted in relation to the
untreated control. The coefficient of variation was always below 15% and is not shown for reasons of clarity
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Figure 2 Quantitation of the HER-2 RNA level in the three different HTB-77
cell lines after treatment with interferon-y(10 ng ml-'). An aliquot (10Ag) of
total RNA isolated after 24 h of treatment were electrophoresed, blotted, and
hybridized as described in Materials and methods. At the bottom, the total
RNA is shown on the ethidium bromide-stained gel
Gif-Sur-Yvette, France) and HLA-DR (anti-HLA-DR, Becton
Dickinson) were diluted 1:3 and 1:64 respectively, after which
50 ,ul oftheantibody solution was added to each well for I h. After
this, the wells were washed and then 75 000 c.p.m. of'215 I-labelled
anti-mouse immunoglobulin F(ab')2 (Amersham International,
Buckingshamshire, UK) was added. After incubation and washing
the cells were lysed with sodium hydroxide (2 M). Radioactivity of
the solution was then measured in a y-scintillation counter
(Berthold, Wildbad, Germany). Background counts, approxi-
mately 200-400 c.p.m., which were determined using a non-
specific mouse serum, were subtracted from counts obtained when
using the specific monoclonal antibodies. Specific binding less
than 100 c.p.m. was considered as negative.
Northern blot
Total cellular RNA was extracted by the guanidine thiocyanate
method as described previously (Widschwendter et al, 1995). An
aliquot (10 ,ug) of total RNA mixed with ethidium bromide was
run ondenaturing I% agarose-formaldehyde gel and transfeffed to
nylon membranes by Northern blotting. The sheet thus prepared
was fixed and photographed under UV light andhybridized with a
digoxigenin-labelled 1.6-kB EcoRI fragment of the pCER204
erbB2 clone (Yamamoto et al, 1986). Detection of digoxigenin-
labelled nucleic acids was carried out using a chemiluminescence
enzyme immunoassay. Filters were exposed to autoradiographic
films. For quantitation, the signal intensities of the autoradio-
graphic films and the ribosomal RNAs in the photographs of the
corresponding blot were scanned.
pl85HER-2 enzyme linked immunosorbent assay (ELISA)
The three different types of HTB-77 cell lines (wt, cDDP and
cDDP + IFN) were cultured with or without addition of IFN-7
(10 ng ml-'). After 3 days' treatment, cells were harvested and
the HER-2 protein was determined with a commercially available
ELISA (Human neu Quantitative ELISA Assay, Oncogene
Research Products, Calbiochem, MA, USA) according to the
manufacturer's instructions.
Statistics
Data were analysed by means of BMDP (Biomedical Data
Package, Sepulveda, CA, USA) software run on an IBM personal
computer. Differences between two medians were estimated by the
Wilcoxon U-test. Differences in depending groups were analysed
by the paired Wilcoxon test.
RESULTS
The wild-type HTB-77 and the cells selected by repeated treatment
with cisplatin alone or in combination with IFN-ywere first tested
for their sensitivity in vitro to cisplatin. Cells were exposed to
increasing concentrations of cisplatin and the antiproliferative
effects were assayed by cell enumeration. The proliferation of
HTB-77wt cells was inhibited by cisplatin in a dose-related manner
(Figure 1), and IC50 was reached at 0.3 ig ml-'. The proliferation
of HTB-77cDDP and HTB-77cDDP + IFN cells was also inhibited by
cisplatin, but about three times higher concentrations were
required to obtain a 50% reduction in cell number (P < 0.01). In
both types of HTB-77 cell lines that had been selected with
cisplatin-incubation showed the same responsiveness to cisplatin
whether or not they had been pretreated with IFN-y(NS).
In addition to cisplatin, the cells were also tested for their sensi-
tivity to IFN-y. This was interesting as only one cell line, namely
HTB-77CDDP + IFNI had been exposed during the 8 months of
repeated treatment to IFN-y. IFN-y reduced the number of HTB-
77w, cells in a dose-related manner and IC50 was achieved at
0.3 ng ml-' (Figure 1). Both types of cisplatin-treated HTB-77
cells were, however, more resistant to IFN-y alone than was the
wild type (P < 0.01). The IC50 could notbe reached by HTB-77CDDp
and HTB-77CDDP+IFN cells even at the highest dose applied, namely
100 ng ml-'. We could not observe a significant difference
regarding the IFN-y responsiveness between the HTB-77CDDP and
HTB-77cDDP+IFN cells.
Ovarian carcinoma cells respond to an IFN-ychallenge not only
with reduced growth but also with the increased expression of
tumour-associated antigens and antigens ofthe majorhistocompat-
ibility complex (Marth et al, 1989a). We were therefore interested
in whether IFN-y resistance is associated with reduced antigen
expression. All HTB-77 cell types analysed did not express
measurable amounts ofeither CA-125 or HLA-DR on their surface
(Table 1). However, after incubation with IFN-y for 3 days, all
three cell types exposed the tumour marker CA-125 and HLA-DR
on their surface (P < 0.01 for each comparison). This increase,
however, was less pronounced in HTB-77wt than in the two other
cell lines. Differences in CA-125 or HLA-DR expression after
IFN-y treatment between HTB-77CDDP and HTB-77CDDP + IFN were
not statistically significant.
Expression ofthe HER-2 proto-oncogene has been shown to be
suppressed by IFN-y, and this effect has been considered to be the
mechanism of interferon-mediated growth inhibition (Marth et al,
1990). We were therefore interested in whether the resistant cell
lines further reduce HER-2 expression upon IFN-y treatment.
Moreover, reduced expression ofHER-2 in cisplatin-resistant cells
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has been described recently (Langton-Webster et al, 1994). In our
experiments, however, the concentration of p185HER-2 was signifi-
cantly higher in eitherHTB-77CDDP orHTB-77CDDP+IFN cells than in
the wild-type cells (Table 2). A 3-day treatment with IFN-y
resulted in a significant reduction in the concentration ofthe onco-
gene product expressed as HER-2/neu arbitrary units per mg of
protein in the three cell lines. Using total RNA, two specific tran-
scripts of the HER-2 gene of 4.5 kb and 10 kb were detected
as described previously Marth et al, 1990 (Figure 2). The
RNA concentrations were lowest in HTB-77wt (100%), higher in
HTB-77CDDp (145%) and highest in HTB-77CDDP+ FN (192%), cells.
The addition ofIFN-yresulted in a marked reduction in the detec-
tion limit of both species of transcripts (20%, 18% and 15%
respectively).
DISCUSSION
Most ovarian carcinoma patients will be treated with a platinum-
containing regimen, whereby several cycles with a relatively short
duration of effective drug maintenance will be administered. In
agreement with Langton-Webster et al (1994), we attempted to
mimic the clinical situation by treating an ovarian carcinoma cell
line with intermittent cycles ofcisplatin in vitro. Moreover, in one
group of cells each cycle was preceded by treatment with IFN-Y.
The results we present indicate that cisplatin-resistant variants of
the HTB-77 cells can be derived using this regimen, whereby the
IFN-y treatment failed in preventing the occurrence of cisplatin
resistance.
Cisplatin resistance was accompanied by an increased expres-
sion of HER-2 protein and RNA levels. This finding is in agree-
ment with earlier studies suggesting that HER-2 overexpression is
associated with a poor drug response. Benz et al (1991) showed
that transfection of MCF-7 breast cancer cells with HER-2
decreased sensitivity to cisplatin and tamoxifen. Similarly,
Langton et al (1993) achieved increased cisplatin resistance in a
human mammary cell line by transfection with HER-2. Cells in
which HER-2 expression becomes elevated may attain a selective
advantage in cell proliferation and thus survive chemotherapy.
Moreover, in non-small-cell lung cancer cells, high levels of
p185HER-2 are correlated with intrinsic chemoresistance to cisplatin
and also to doxorubicin and etoposide (Tsai et al, 1996). As in
HER-2, elevated c-myc expression upon cisplatin treatment has
been described (Walker et al, 1996). Data obtained from clinical
trials suggest that overexpression of HER-2 is associated with
resistance to conventional doses of cytostatic agents, including
cisplatin (Hayes, 1996).
Although in this study cisplatin resistance was also associated
with elevated HER-2 expression, inhibition of the expression of
this oncogene by IFN-y did not restore cisplatin sensitivity. We
therefore conclude that resistance is not caused by HER-2
augmentation but is only associated with it. On the other hand,
down-regulation ofHER-2 by antibodies recognizing the extracel-
lular epitope ofpI85HER-2 produced, in combination with cisplatin,
a synergistic decrease in proliferation of breast and ovarian carci-
noma cells (Arteaga et al, 1994; Pietras et al, 1994). As interferons
also down-regulate the HER-2 message (Marth et al, 1990) it is
plausible that they may induce the synergistic interaction by
similar mechanisms. This could also be concluded from the effects
of tyrphostin AG825, a tyrosine kinase inhibitor, which reduces
HER-2 activity and enhances the chemosensitivity of high-
p185HER-2-expressing cell lines, whereas it had little effect on the
chemosensitivities of the low-p 185HER-2-expressing cells (Tsai et
al, 1996). For clinical trials, therefore, the combination of a
substance that reduces HER-2 activity with cisplatin seems inter-
esting. Potential candidates are p185HER-2 antibodies, interferons or
specific tyrosine kinase inhibitors (Zhang and Hung, 1996).
An interesting finding of this study was the cross-resistance of
cisplatin-treated cells with IFN-y. The reduced antiproliferative
activity of this cytokine was not dependent on IFN-y exposure
before cisplatin exposure. Treatment with cisplatin affects the
responsiveness of ovarian carcinoma cells to a variety of
substances, including cytostatic agents such as doxorubicin,
mitoxantrone or paclitaxel, and also to irradiation (Hamaguchi et
al, 1993). Our report, for the first time, also describes a cross-
resistance to interferons. The mechanism ofthis broad induction of
resistance remains unknown, as for most of these substances
different mediators of action have been discussed. Surprisingly,
however, interferon resistance was observed for its antiprolifera-
tive activity only. The induction ofCA-125 and HLA-DR expres-
sion as well as the suppression of HER-2 oncogene RNA and
protein was not reduced in both cisplatin-resistant HTB-77 cell
lines, indicating a lack of correlation between antigen expression
and cisplatin sensitivity. This is in agreement with earlier findings
indicating adissociation ofantiproliferative activity and regulation
of antigen expression: an IFN-y-resistant variant of the human
breast cancer cell line BT-20 responded to IFN-y challenge with
augmented HLA-DR expression, whereas proliferation was not
affected (Marth etal, 1987). Recentevidence demonstrates that the
response of interferon-induced genes to IFN-y depends on a co-
operative role of IFN-y-responsive factors binding to the inter-
feron-stimulated response element (ISRE) and IFN-yactivated site
(GAS) elements (Chon et al, 1996). Defects in transcription
factors occurring in resistant cells could result in altered binding to
the different promoter regions of interferon-induced genes and
thus explain selective resistance (Guille et al, 1994). In a recent
clinical trial, however, Pujade-Lauraine et al (1996) described that
response to intraperitoneal IFN-y was not reduced in cisplatin-
resistant ovarian cancer patients. This could indicate that
mechanisms other than the direct antiproliferative activity play an
important role in vivo. Activation ofimmune effector cells, such as
peritoneal macrophages, by IFN-y may be one possibility.
Moreover, IFN-y induced expression of tumour-associated anti-
gens and HLA-DR that is not reduced in cisplatin-resistant cells
could increase the sensitivity of ovarian carcinoma cells to cell-
mediated cytotoxicity.
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